pifithrin has been researched along with Carcinoma, Lewis Lung in 1 studies
pifithrin: a tetrahydrobenzothiazol; inhibitor of P53 that protects mice from the side effects of cancer therapy; structure in first source
Carcinoma, Lewis Lung: A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burdelya, LG | 1 |
| Komarova, EA | 1 |
| Hill, JE | 1 |
| Browder, T | 1 |
| Tararova, ND | 1 |
| Mavrakis, L | 1 |
| DiCorleto, PE | 1 |
| Folkman, J | 1 |
| Gudkov, AV | 1 |
1 other study available for pifithrin and Carcinoma, Lewis Lung
| Article | Year |
|---|---|
Inhibition of p53 response in tumor stroma improves efficacy of anticancer treatment by increasing antiangiogenic effects of chemotherapy and radiotherapy in mice.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Benzothiazoles; Carcinoma, Lewi | 2006 |